Yonjin is an investment firm that makes an investment in early and mid-stage life science industries.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Yonjin is an investment firm that makes an investment in early and mid-stage life science industries.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
10/2022 | Intressa Vascular | Funding Round | 12M |
7/2017 | Decipher Biosciences | Series C | - |
7/2017 | Frequency Therapeutics | Series B | - |
6/2020 | C4 Therapeutics | Series B | 150M |
3/2021 | OncoResponse | Series C | 0 |
3/2017 | Mesa Biotech | Series B | - |
6/2016 | Janssen Global Services | Series A | - |
10/2020 | Shenzhen Anteland Technology Co., Ltd. | Series A | 3.7M |
6/2020 | HistoSonics | Series C | 40M |
2/2021 | NanoCellect Biomedical | Series C | 0 |
1/2020 | EvolveImmune Therapeutics | Venture Round | 17.5M |
12/2019 | Metabomed | Series B | 0 |
12/2022 | HistoSonics | Convertible Note | 85M |
8/2022 | Regenacy Pharmaceuticals | Series B | 0 |
3/2020 | Regenacy Pharmaceuticals | Series A | - |
9/2020 | Libra Therapeutics | Series A | 29M |
8/2022 | Bluejay Therapeutics | Series B | 0 |
3/2021 | OncoResponse | Series C | 0 |
2/2021 | NanoCellect Biomedical | Series C | 0 |
10/2020 | Shenzhen Anteland Technology Co., Ltd. | Series A | 0 |
9/2020 | Libra Therapeutics | Series A | 0 |
6/2020 | C4 Therapeutics | Series B | 0 |
6/2020 | HistoSonics | Series C | 0 |
3/2020 | Regenacy Pharmaceuticals | Series A | 0 |
1/2020 | EvolveImmune Therapeutics | Venture Round | 0 |
12/2019 | Metabomed | Series B | 0 |
7/2017 | Frequency Therapeutics | Series B | - |
Name | Price |
---|
Name | Size | Announced Date |
---|